Ad
related to: new fda approved medications 2022 free program
Search results
Results from the WOW.Com Content Network
Mavacamten. Mavacamten, sold under the brand name Camzyos, is a medication used to treat obstructive hypertrophic cardiomyopathy. [8][9] Mavacamten is a small-molecule allosteric [10] and cardiac myosin inhibitor. [8] It was developed by MyoKardia, a subsidiary of Bristol Myers Squibb. [11] In clinical studies, mavacamten has demonstrated ...
Lenacapavir was approved for medical treatment in the European Union in August 2022, [10] [12] in Canada in November 2022, [5] [6] and in the United States in December 2022. [9] [11] [13] [14] It is the first of a class of drugs called capsid inhibitors to be approved by the US Food and Drug Administration (FDA) for treating HIV/AIDS. [11] [15]
Tirzepatide was approved for treatment of diabetes in the United States in May 2022, [10] [13] in the European Union in September 2022, [12] in Canada in November 2022, [18] and in Australia in December 2022. [2] The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Ozempic isn’t FDA-approved to treat weight loss in people with obesity, but it’s often used off-label for this purpose. Off-label is when a healthcare professional prescribes a medication for ...
Dostarlimab was approved for the treatment of endometrial cancer in both the United States and the European Union in April 2021. [5] [6] [11] [8] [12] Based on the Garnet trial, dostarlimab gained accelerated approval from the US Food and Drug Administration (FDA) in April 2021, [6] and full approval in February 2023. [7]
The approval comes after several doctors who treat patients with ALS pleaded with the FDA in a letter to approve Relyvrio, which has the scientific name AMX0035. The letter acknowledged that data ...
The gene therapy will compete with Australia-based CSL Behring’s Hemgenix, a similar treatment that won FDA approval for hemophilia B in 2022. That drug has a similar list price of $3.5 million ...
Amgen. non-small cell lung cancer with KRAS G12C mutation. Avapritinib. Blueprint Medicines Corp. granted for two indications: mast cell leukemia and advanced systemic mastocytosis. Belumosudil. Kadmon Pharmaceuticals. chronic graft-versus-host disease. Pembrolizumab.
Ad
related to: new fda approved medications 2022 free program